Ibcasertib

Drug Overview

Ibcasertib (also known by its developmental code CS2164 and synonym chiauranib) is an investigational, orally bioavailable, small-molecule multi-kinase inhibitor. It is designed to target a specific profile of serine-threonine and tyrosine kinases that drive tumor growth, survival, and the formation of new blood vessels.

In the clinical landscape of March 2026, ibcasertib is recognized for its “three-pathway” approach to cancer therapy. Unlike many inhibitors that focus on a single target, ibcasertib simultaneously inhibits Aurora kinase B, Vascular Endothelial Growth Factor Receptors (VEGFR 1-3), and other critical receptors like c-KIT and PDGFR. This multi-targeted mechanism is intended to kill cancer cells directly (anti-proliferation), starve the tumor of its blood supply (anti-angiogenesis), and disrupt the tumor’s supportive environment (anti-stroma). Developed by Chipscreen Biosciences, ibcasertib is currently in advanced Phase II and Phase III clinical trials, primarily in China and the United States, for a range of difficult-to-treat malignancies including small cell lung cancer (SCLC) and Non-Hodgkin Lymphoma.

• Generic Name: Ibcasertib.
• Synonym: Chiauranib.
• Code Name: CS2164.
• Drug Class: Multi-Kinase Inhibitor; Aurora B/VEGFR/c-KIT/PDGFR Inhibitor.
• Mechanism: Direct inhibition of tumor cell division (Aurora B) and suppression of tumor blood vessel growth (VEGFR/PDGFR).
• Route of Administration: Oral (Capsule).
• FDA Approval Status: Investigational. As of March 2026, ibcasertib is not FDA-approved. It has been granted Orphan Drug Designation for small cell lung cancer (SCLC) and is currently in Phase III evaluation for SCLC and Phase II for other indications.

What Is It and How Does It Work? (Mechanism of Action)

Ibcasertib works by “jamming” several critical signaling pathways that cancer cells use to grow and spread throughout the body.

1. Direct Anti-Tumor Activity (Aurora Kinase B)

Aurora kinase B is a protein essential for mitosis (cell division). It ensures that chromosomes are correctly sorted when a cell splits into two.

• The Blockade: Ibcasertib inhibits Aurora B, causing the cancer cell to fail during division.
• Mitotic Catastrophe: This leads to “mitotic catastrophe,” where the cell becomes unstable and triggers apoptosis (programmed cell death).

2. Cutting Off the Food Supply (Anti-Angiogenesis)

Tumors need a constant supply of blood to grow beyond a few millimeters. They send out signals like VEGF to force the body to grow new blood vessels toward the tumor.

• The Switch: Ibcasertib blocks VEGFR 1, 2, and 3 and PDGFR, the “receptors” that receive these growth signals.
• Starvation: By preventing new vessel growth, the drug essentially “starves” the tumor of oxygen and nutrients.

3. Targeting the Tumor Support (c-KIT & PDGFR)

The drug also inhibits c-KIT and PDGFR, which are often mutated or overexpressed in certain cancers. These proteins help the tumor interact with the “stroma” (the connective tissue and immune cells surrounding the tumor), making it easier for the cancer to survive and resist treatment.

Clinical Indications and Research Status (2026)

In 2026, ibcasertib is being prioritized for cancers that have historically had few effective targeted therapy options:

• Small Cell Lung Cancer (SCLC): This is the most advanced area of research. In late 2025, Phase III data from China showed that ibcasertib significantly improved Progression-Free Survival (PFS) in patients who had failed at least two prior lines of chemotherapy. It holds Orphan Drug Designation for this use in the U.S.
• Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): Currently in Phase II trials (e.g., NCT03974243). Ibcasertib is being evaluated both as a single agent and in combination with other drugs like chidamide (an HDAC inhibitor) to see if the two can “double-hit” the cancer’s survival pathways.
• Ovarian Cancer: Investigated for its ability to treat platinum-resistant ovarian cancer, where its anti-angiogenic properties are of particular interest.
• Hepatocellular Carcinoma (Liver Cancer): Early trials have suggested that ibcasertib may be effective in shrinking liver tumors that have become resistant to other kinase inhibitors like sorafenib.

Dosage and Administration Protocols

As an investigational agent, the dosing of ibcasertib is established through clinical trial protocols to optimize safety.

Clinical Efficacy and Research Results (2024–2026)

Recent data have refined our understanding of how this multi-kinase approach compares to older therapies:

• SCLC Breakthrough: 2025 Phase III results indicated that ibcasertib provided a meaningful survival benefit for third-line SCLC, a population that previously had no approved standard of care.
• Lymphoma Response: In early 2026, researchers reported that the combination of ibcasertib and chidamide achieved an Overall Response Rate (ORR) of over 40% in patients with certain types of aggressive T-cell lymphoma.
• Vascular Targeting: Pharmacodynamic studies have confirmed that the drug successfully reduces “circulating endothelial cells,” a marker proving that it is successfully hitting its anti-angiogenesis targets in the body.

Safety Profile and Side Effects

The side effects of ibcasertib are characteristic of multi-kinase inhibitors, particularly those that block blood vessel growth.

1. Vascular and Skin Effects

• Hypertension (High Blood Pressure): The most common side effect due to VEGFR inhibition.
• Hand-Foot Skin Reaction: Redness, swelling, and pain on the palms of the hands and soles of the feet.

2. Gastrointestinal Issues

• Symptoms: Diarrhea, nausea, and decreased appetite were reported in over 30% of patients in Phase II trials.

3. Hematologic Toxicity

• Neutropenia and Thrombocytopenia: Lowered white blood cell and platelet counts. This is often linked to the Aurora B inhibition, which can affect healthy bone marrow cells.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, ibcasertib is used to study “Vascular Niche Maintenance.” Researchers are investigating how “quieting” VEGFR signaling affects the ability of Hematopoietic Stem Cells to remain healthy during cancer treatment. In 2026, there is also focus on “Immune-Cold Tumors,” where scientists are looking at whether ibcasertib’s ability to “normalize” tumor blood vessels can make it easier for T-cells to enter the tumor, potentially paving the way for combinations with immunotherapy.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Cardiovascular Check: Baseline blood pressure and EKG to monitor for vascular side effects.
• Liver Function Test: Baseline monitoring of AST/ALT and bilirubin.

“Do’s and Don’ts” List:

• DO monitor your blood pressure at home; hypertension is common and can usually be managed with standard blood pressure medications.
• DO use a thick, alcohol-free moisturizer on your hands and feet to prevent the “hand-foot” skin reaction.
• DON’T ignore sudden “abdominal pain” or “black, tarry stools,” which could be signs of rare but serious GI bleeding or perforation linked to anti-angiogenic drugs.
• DON’T take any “herbal supplements” (like St. John’s Wort) without checking with your oncologist, as they can change how ibcasertib is absorbed by your liver.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Ibcasertib (chiauranib) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist regarding your specific diagnosis and eligibility for active clinical research.